Amyotrophic Lateral Sclerosis Key Players – Daval International Ltd, Eisai Co Ltd, and Neurotune AG Ltd Market Analysis & Forecast 2024

Amyotrophic Lateral Sclerosis 

Overview

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis).

Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Click here for sample report @ https://www.wiseguyreports.com/sample-request/2450266-amyotrophic-lateral-sclerosis-pipeline-review-h2-2017

 

Top Companies mentioned

2-BBB Medicines BV

AB Science SA

BrainStorm Cell Therapeutics Inc

Catabasis Pharmaceuticals Inc

Daval International Ltd

Eisai Co Ltd

Mitsubishi Tanabe Pharma Corp

Neurotune AG

Orphazyme ApS

Pharnext SA

Major Highlight

Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 3, 25, 12, 2, 75, 18 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 41 and 7 molecules, respectively.

Amyotrophic Lateral Sclerosis pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

.Continued

For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/2450266-amyotrophic-lateral-sclerosis-pipeline-review-h2-2017

Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

WISEGUY RESEARCH CONSULTANTS PVT LTD
Office No. 528, Amanora Chambers
Pune - 411028
Maharashtra, India

This release was published on openPR.